10x Genomics (NASDAQ:TXG) Receives "Sell (E+)" Rating from Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "Sell (E+)" rating for 10x Genomics (NASDAQ:TXG), indicating a negative outlook from this financial analyst.
• Other analysts have varied opinions with UBS Group upgrading their target to $13.00 and rating it "neutral," while Deutsche Bank set a target of $14.00 with a "hold" rating.
• 10x Genomics reported a quarterly profit of $0.28 EPS, exceeding estimates, with revenues increasing 12.9% year-over-year to $172.91 million.

Weiss Ratings restated their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG - Free Report) in a research note published on Saturday, September 13th,Weiss Ratings reports.

Several other brokerages have also recently weighed in on TXG. Wall Street Zen cut 10x Genomics from a "buy" rating to a "hold" rating in a report on Saturday, September 13th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the stock a "hold" rating in a report on Friday, August 8th. Bank of America lifted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Barclays reiterated an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Finally, Piper Sandler assumed coverage on 10x Genomics in a report on Thursday, September 11th. They set a "neutral" rating and a $15.00 price target for the company. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $13.65.

10x Genomics Stock Down 1.7%

10x Genomics stock traded down $0.23 during mid-day trading on Friday, hitting $13.04. 3,262,793 shares of the company's stock were exchanged, compared to its average volume of 2,167,720. The firm has a market capitalization of $1.62 billion, a P/E ratio of -18.63 and a beta of 2.00. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $23.53. The company's 50 day simple moving average is $13.29 and its 200-day simple moving average is $10.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm's revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Research analysts expect that 10x Genomics will post -1.43 EPS for the current year.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares in the company, valued at $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the sale, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock valued at $539,865 over the last quarter. 9.39% of the stock is owned by company insiders.

Institutional Trading of 10x Genomics

Several institutional investors have recently modified their holdings of the business. Teacher Retirement System of Texas grew its holdings in 10x Genomics by 6.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 14,931 shares of the company's stock worth $173,000 after acquiring an additional 858 shares during the last quarter. Allworth Financial LP boosted its stake in shares of 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company's stock valued at $26,000 after purchasing an additional 1,364 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of 10x Genomics by 48.1% during the 2nd quarter. Blue Trust Inc. now owns 4,894 shares of the company's stock valued at $57,000 after purchasing an additional 1,590 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after purchasing an additional 1,614 shares in the last quarter. Finally, Xponance Inc. boosted its stake in shares of 10x Genomics by 17.4% during the 1st quarter. Xponance Inc. now owns 12,010 shares of the company's stock valued at $105,000 after purchasing an additional 1,778 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.